| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Bevacizumab targets tumor angiogenesis, which is the standard approach to be combined with chemotherapy. Also, the number of circulating EPCs is known to be tumor angiogenesis marker. This study aimed to investigate the association between the number of EPCs when treated with chemotherapy in combination with bevacizumab and the disease outcomes in NSCLC patients.
We identified NSCLC patients who had not received any treatment. We divided into two groups relative to the level of EPCs. In each group we compared the tumor reduction ratio, progression-free survival, the objective response ratio, and the disease control ratio with or without administering Bevacizumab in combination. Only in the high EPC group, chemotherapy in combination with bevacizumab produced a significantly higher tumor reduction ratio and ORR and significantly longer PFS compared to the absence of bevacizumab. The number of EPCs may act as a biomarker for predicting the additional effect of Bev. in NSCLC patients.
|
